Maxcyte (MXCT) EBT Margin (2020 - 2025)
Historic EBT Margin for Maxcyte (MXCT) over the last 6 years, with Q3 2025 value amounting to 181.81%.
- Maxcyte's EBT Margin fell 402500.0% to 181.81% in Q3 2025 from the same period last year, while for Sep 2025 it was 132.58%, marking a year-over-year decrease of 542100.0%. This contributed to the annual value of 106.29% for FY2024, which is 144400.0% down from last year.
- As of Q3 2025, Maxcyte's EBT Margin stood at 181.81%, which was down 402500.0% from 145.26% recorded in Q2 2025.
- Maxcyte's EBT Margin's 5-year high stood at 26.44% during Q3 2021, with a 5-year trough of 181.81% in Q3 2025.
- Over the past 5 years, Maxcyte's median EBT Margin value was 89.89% (recorded in 2024), while the average stood at 91.94%.
- As far as peak fluctuations go, Maxcyte's EBT Margin soared by 743000bps in 2022, and later plummeted by -917900bps in 2023.
- Quarter analysis of 5 years shows Maxcyte's EBT Margin stood at 48.01% in 2021, then increased by 19bps to 38.71% in 2022, then grew by 13bps to 33.69% in 2023, then tumbled by -262bps to 121.9% in 2024, then tumbled by -49bps to 181.81% in 2025.
- Its EBT Margin was 181.81% in Q3 2025, compared to 145.26% in Q2 2025 and 98.76% in Q1 2025.